Kangtai Biotech: Bivalent Inactivated Enterovirus Vaccine Initiates Phase I Clinical Trial.

Kangtai Biotech announced that its wholly-owned subsidiary Beijing Minhai Biotechnology Co., Ltd. has completed the preparation work for Phase I clinical trials of the bivalent enterovirus inactivated vaccine developed by the company, and has initiated Phase I clinical trials, successfully completing the enrollment for the first subject. The vaccine is suitable for individuals aged 6 months and older who are susceptible to EV-A71 and CV-A16, and is used to prevent hand, foot, and mouth disease and other infectious diseases caused by enterovirus EV-A71 and CV-A16 infections. Currently, this vaccine has not been approved for marketing worldwide.